At 12weeks , more patients in the liraglutide compared with the sulphonylurea group achieved a composite endpoint of haemoglobin A1c ( HbA1c ) < 7 % , no weight gain and no severe hypoglycaemia but this did not reach statistical significance [ odds ratio ( OR ) 4.08 , 95 % confidence interval ( CI ) 0.97 , 17.22 , p = 0.06 ] .